Similarly, the human epidermal growth factor receptor 2 (HER2)-DC1 vaccine, when combined with anti-HER2 therapy and anti-PD-1, induces infiltration of both CD4 and CD8 T cells into tumors, leading to increased survival in preclinical models of HER2-positive breast cancer [54]. This evidence concerns the gene ERBB2 and breast carcinoma.